Analytical Data
-
Gene name
POLg1
- Application
-
Alternative Names
PEO; POLG1; POLGA; SANDO; SCAE; Mitochondrial DNA polymerase catalytic subunit
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P54098
-
Expression Region
Trp1041~Pro1239
-
Molecular Weight
22&26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
POLG1, or mitochondrial DNA polymerase gamma, is a crucial enzyme that plays a key role in the replication and maintenance of mitochondrial DNA (mtDNA). Mitochondria are the powerhouses of the cell, generating energy through oxidative phosphorylation, and their proper functioning is essential for cellular metabolism and overall health. Mutations in the POLG1 gene can lead to a variety of mitochondrial diseases characterized by energy deficiencies and a wide range of clinical manifestations, including neurodegenerative disorders, myopathies, and susceptibility to aging. The study of POLG1 recombinant proteins has gained traction as researchers seek to understand the molecular mechanisms underlying its enzymatic activity and the pathogenic effects of specific mutations. By producing and characterizing POLG1 recombinant proteins in vitro, scientists can elucidate the structure-function relationships of this enzyme, assess its fidelity and processivity in DNA synthesis, and explore potential therapeutic interventions. Additionally, the recombinant approach enables the study of POLG1 interactions with various cofactors and other mitochondrial proteins, further enriching our understanding of mitochondrial biology and the implications of POLG1 dysfunction in disease. As mitochondrial DNA plays a pivotal role in inherited metabolic disorders and age-related pathologies, POLG1 remains a significant focus in mitochondrial research, with the potential to lead to advancements in gene therapy and targeted treatments.
